It is estimated that one-third of the world's population is infected with Mycobacterium tuberculosis and that tuberculosis (TB) kills more than 2 million people each year (4). Intradermal vaccination of infants with the currently available TB vaccine Mycobacterium bovis bacillus Calmette-Guérin (BCG) can induce partial protection against TB disease (7) but does not prevent initial or latent infection with M. tuberculosis. Once infected, individuals are at chronic risk for TB disease progression and secondary transmission, especially when vaccine immunity wanes or is suppressed. Therefore, the development of a more efficacious TB vaccine strategy capable of preventing or eliminating chronic infection is an important goal.Mycobacteria replicate within macrophages in the human host, and defects in cell-mediated immunity result in increased susceptiblity to these intracellular pathogens. Therefore, it can be predicted that memory-immune T cells capable of inhibiting the intracellular growth of mycobacteria are important for in vivo protection against TB. Mycobacteria-specific CD4 ϩ ␣ T cells, CD8 ϩ ␣ T cells, and ␥␦ T cells develop in individuals with partial resistance against TB disease, such as healthy purified protein derivative (PPD)-positive persons latently infected with M. tuberculosis and BCG-vaccinated individuals